Primary Site >> Stomach Cancer

Gene >> UMPS

  • 1996
  • 2000
  • 2001
  • 2004
  • 2005
  • 2006
  • 2007
  • 2008
  • 2009
  • 2010
  • 2011
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
Ref: Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells.
PMID: 8609072
Ref: Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells.
PMID: 10974411
Ref: [Expression and pathophysiologic features of orotate phosphoribosyl transferase activity (OPRT) in gastric carcinoma].
PMID: 11265402
Ref: Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray.
PMID: 15331170
Ref: [Establishment of enzyme-linked immunosorbent assay for quantification of orotate phosphoribosyltransferase in gastric carcinoma].
PMID: 16044965
Ref: Impact of orotate phosphoribosyl transferase activity as a predictor of lymph node metastasis in gastric cancer.
PMID: 16142362
Ref: Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines.
PMID: 16557585
Ref: [Clinicopathological significance of orotate phosphoribosyltransferase in gastric carcinoma].
PMID: 16612158
Ref: Orotate phosphoribosyltransferase levels measured by a newly established enzyme-linked immunosorbent assay in gastric carcinoma.
PMID: 16734727
Ref: Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1.
PMID: 16736497
Ref: [Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer].
PMID: 16897978
Ref: [Clinical and prognostic significance of protein and gene expression of orotate phosphoribosyltransferase in gastric carcinoma].
PMID: 16912530
Ref: The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance.
PMID: 17089033
Ref: Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-fluorouracil on gastric cancer cell lines.
PMID: 17237621
Ref: Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: correlation with drug sensitivity against 5-fluorouracil.
PMID: 17303323
Ref: [Orotate phosphoribosyltransferase levels in gastric carcinoma and normal gastric mucosa - correlation with thymidylate synthase and dihydropyrimidine dehydrogenase levels and the changes after neoadjuvant chemotherapy].
PMID: 17940372
Ref: Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues.
PMID: 18095079
Ref: Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
PMID: 18506536
Ref: Challenge for a better combination with basic evidence.
PMID: 18553230
Ref: [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
PMID: 18633253
Ref: Decreased orotate phosphoribosyltransferase activity produces 5-fluorouracil resistance in a human gastric cancer cell line.
PMID: 19020740
Ref: Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.
PMID: 19020767
Ref: Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma.
PMID: 19084572
Ref: Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
PMID: 19332728
Ref: Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
PMID: 19588501
Ref: [Therapeutic outcome and prognosis in S-1+CDDP chemotherapy for advanced gastric cancer--postoperative histopathological assessment].
PMID: 20332681
Ref: A quantitative evaluation of the determinant proteins for S-1 responsiveness in a biopsy specimen assists in patient selection to neoadjuvant therapy in cases of advanced gastric cancer.
PMID: 20596652
Ref: A predictive factor for the response to S-1 plus cisplatin in gastric cancer.
PMID: 20857529
Ref: Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes.
PMID: 20533001
Ref: Relationship between gene expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in primary cancer cells isolated from malignant ascites.
PMID: 21210725
Ref: Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer.
PMID: 21572321
Ref: S-1 and the treatment of gastric cancer with peritoneal dissemination.
PMID: 22977609
Ref: [Correlated analysis of 5 fluorouracil metabolic enzymes with tumor response after SOX regimen neoadjuvant chemotherapy in advanced gastric cancer].
PMID: 24721353
Ref: Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.
PMID: 25112781
Ref: Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
PMID: 25793299
Ref: High/positive expression of 5-fluorouracil metabolic enzymes predicts better response to S-1 in patients with gastric cancer: a meta-analysis.
PMID: 27012156
Ref: ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients.
PMID: 27487151
Ref: Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.
PMID: 27913881
Ref: The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells.
PMID: 30276573